Enzalutamide, however, had no effect on the proliferation of MDA MB 231 (ER-AR-) cells (Figure 1D), indicating that the presence of AR is required for the growth inhibitory properties of enzalutamide on breast cancer cells. Here, AR is linked to breast carcinoma.